The Impact of Translational Research in Breast Cancer Care: Can we Improve the Therapeutic Scenario?
Giuseppe Buono(Federico II University Hospital), Mario Giuliano(Regione Campania), Grazia Arpino(University of Naples Federico II), Roberto Bianco(Federico II University Hospital), Carmen Criscitiello(University of Milan), Sabino De Placido, Francesco Perri(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Francesco Schettini(Target (United States))
Cited by 3
Related Papers
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer
|Annals of Oncology|2021|724
Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
|Endocrine Reviews|2008|545
A Renewable Tissue Resource of Phenotypically Stable, Biologically and Ethnically Diverse, Patient-Derived Human Breast Cancer Xenograft Models
|Cancer Research|2013|485
Taxane-Based Combinations As Adjuvant Chemotherapy of Early Breast Cancer: A Meta-Analysis of Randomized Trials
|Journal of Clinical Oncology|2007|413